Treatment of Payments in Lieu of Taxes Under Section 141, 77352 [E6-22017]
Download as PDF
<![CDATA[
mstockstill on PROD1PC61 with PROPOSALS
77352
Federal Register / Vol. 71, No. 247 / Tuesday, December 26, 2006 / Proposed Rules
heartburn, upset stomach, or stomach
pain [bullet] ulcers [bullet] bleeding
problems [bullet] high blood pressure
[bullet] heart or kidney disease [bullet]
taken a diuretic [bullet] reached age 60
or older’’.
(C) The labeling states ‘‘Ask a doctor
or pharmacist before use if you are
[heading in bold type] [bullet] taking
any other drug containing an NSAID
(prescription or nonprescription [bullet]
taking a blood thinning (anticoagulant)
or steroid drug [bullet] under a doctor’s
care for any serious condition [bullet]
taking any other drug’’.
*
*
*
*
*
(E) In addition to the warning
required in § 201.324(c) of this chapter
after the subheading ‘‘Stop use and ask
a doctor if’’ [heading in bold type], the
following statements also appear:
‘‘[bullet] you feel faint, vomit blood, or
have bloody or black stools. These are
signs of stomach bleeding. [bullet] pain
gets worse or lasts more than 10 days
[bullet] fever gets worse or lasts more
than 3 days [bullet] stomach pain or
upset gets worse or lasts [bullet] redness
or swelling is present in the painful area
[bullet] any new symptoms appear‘‘.
*
*
*
*
*
(2) * * *
(i) For products containing any
ingredient in § 343.10 (a) through (f) The
labeling states ‘‘Stop use and ask a
doctor if [heading in bold type] [bullet]
pain gets worse or lasts more than 5
days [bullet] fever gets worse or lasts
more than 3 days [bullet] redness or
swelling is present [bullet] any new
symptoms appear ’’.
*
*
*
*
*
(iii) For products containing
acetaminophen identified in § 343.10(a).
The labeling states the warnings in
§ 201.325(a)(1)(iv)(A)(1), (a)(1)(iv)(A)(2),
and (a)(1)(iv)(A)(3) and the following
statement must follow the general
warning identified in § 330.1(g) of this
chapter: ‘‘Prompt medical attention is
critical even if you do not notice any
signs or symptoms.’’
(iv) * * *
(A) The labeling states the warning in
paragraph (c)(2)(v)(B) plus the bulleted
statement ‘‘asthma’’.
*
*
*
*
*
(v) * * *
(A) The labeling states the warning in
paragraph (c)(2)(i) of this section plus
‘‘[bullet] the child feels faint, vomits
blood, or has bloody or black stools.
These are signs of stomach bleeding.
[bullet] stomach pain or upset gets
worse or lasts [bullet] ringing in the ears
or loss of hearing occurs’’.
(B) The labeling states ‘‘Ask a doctor
before use if the child has [heading in
VerDate Aug<31>2005
13:25 Dec 22, 2006
Jkt 211001
bold type] [bullet] stomach problems
that last or come back, such as
heartburn, upset stomach, or stomach
pain [bullet] ulcers [bullet] bleeding
problems [bullet] not been drinking
fluids [bullet] lost a lot of fluid due to
vomiting or diarrhea [bullet] high blood
pressure [bullet] heart or kidney disease
[bullet] taken a diuretic’’.
(C) The labeling states ‘‘Ask a doctor
or pharmacist before use if the child is
[heading in bold type] [bullet] taking
any other drug containing an NSAID
(prescription or nonprescription)
[bullet] taking a blood thinning
(anticoagulant) or steroid drug [bullet]
taking a prescription drug for diabetes,
gout, or arthritis’’.
*
*
*
*
*
(3) * * *
(i) For products containing any
ingredient in § 343.10 (a) through (f).
The labeling states ‘‘Stop use and ask a
doctor if [heading in bold type] [bullet]
adult’s pain gets worse or lasts more
than 10 days [bullet] child’s pain gets
worse or lasts more than 5 days [bullet]
fever gets worse or lasts more than 3
days [bullet] redness or swelling is
present [bullet] any new symptoms
appear’’.
(ii) The warning in § 343.50(c)(1)(ii), if
applicable.
(iii) For products containing
acetaminophen identified in § 343.10(a).
The labeling states the warnings in
§ 201.325(a)(1)(v) of this chapter. The
warning in § 201.325 (a)(1)(v)(B) is
modified to read: ‘‘ Ask a doctor before
use if the user [heading in bold type]
[bullet] has liver disease [bullet] is a
child with pain of arthritis’’. The
following statement must follow the
general warning identified in § 330.1(g)
of this chapter: ‘‘Prompt medical
attention is critical for adults as well as
for children even if you do not notice
any signs or symptoms.’’
(iv) The warnings in § 343.50(c)(1)(iv),
if applicable.
(v) For products containing aspirin,
carbaspirin calcium, choline salicylate,
magnesium salicylate, or sodium
salicylate identified in §§ 343.10(b), (c),
(d), (e) and ( f).
(A) The labeling states the warning in
paragraph (c)(3)(i) of this section plus
‘‘[bullet] the user feels faint, vomits
blood, or has bloody or black stools.
These are signs of stomach bleeding.
[bullet] stomach pain or upset gets
worse or lasts [bullet] ringing in the ears
or loss of hearing occurs’’.
(B) The labeling states the warning in
§ 201.325(a)(2)(v)(B) plus ‘‘[bullet] is a
child with pain of arthritis’’.
(C) The labeling states the warning in
§ 201.325(a)(2)(v)(C) plus ‘‘[bullet]
PO 00000
Frm 00043
Fmt 4702
Sfmt 4702
taking a prescription drug for diabetes,
gout, or arthritis’’.
Dated: November 22, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–21855 Filed 12–19–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF THE TREASURY
Internal Revenue Service
26 CFR Part 1
[REG–136806–06]
RIN 1545–BF87
Treatment of Payments in Lieu of
Taxes Under Section 141
Internal Revenue Service (IRS),
Treasury.
AGENCY:
Change of location of public
hearing.
ACTION:
SUMMARY: On October 19, 2006, on page
61693 of the Federal Register (71 FR
61693), a notice of proposed rulemaking
and notice of public hearing announced
that a public hearing concerning
applying the private security or
payment test for State and local
governmental issuers of tax-exempt
bonds will be held February 13, 2007 in
the auditorium of the New Carrollton
Federal Building, 5000 Ellin Road,
Lanham, MD 20706. The location of the
public hearing has changed.
The public hearing will be
held in the IRS Auditorium, Internal
Revenue Building, 1111 Constitution
Avenue, NW., Washington, DC.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Concerning submissions of comments,
the hearing, and/or to be placed on the
building access list to attend the hearing
Kelly Banks, (202) 622–0392 (not a tollfree number).
LaNita Van Dyke,
Branch Chief, Publications and Regulations,
Associate Chief Counsel, Legal Processing
Division, (Procedure and Administration).
[FR Doc. E6–22017 Filed 12–22–06; 8:45 am]
BILLING CODE 4830–01–P
E:\FR\FM\26DEP1.SGM
26DEP1
]]>Agencies
[Federal Register Volume 71, Number 247 (Tuesday, December 26, 2006)]
[Proposed Rules]
[Page 77352]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-22017]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF THE TREASURY
Internal Revenue Service
26 CFR Part 1
[REG-136806-06]
RIN 1545-BF87
Treatment of Payments in Lieu of Taxes Under Section 141
AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Change of location of public hearing.
-----------------------------------------------------------------------
SUMMARY: On October 19, 2006, on page 61693 of the Federal Register (71
FR 61693), a notice of proposed rulemaking and notice of public hearing
announced that a public hearing concerning applying the private
security or payment test for State and local governmental issuers of
tax-exempt bonds will be held February 13, 2007 in the auditorium of
the New Carrollton Federal Building, 5000 Ellin Road, Lanham, MD 20706.
The location of the public hearing has changed.
ADDRESSES: The public hearing will be held in the IRS Auditorium,
Internal Revenue Building, 1111 Constitution Avenue, NW., Washington,
DC.
FOR FURTHER INFORMATION CONTACT: Concerning submissions of comments,
the hearing, and/or to be placed on the building access list to attend
the hearing Kelly Banks, (202) 622-0392 (not a toll-free number).
LaNita Van Dyke,
Branch Chief, Publications and Regulations, Associate Chief Counsel,
Legal Processing Division, (Procedure and Administration).
[FR Doc. E6-22017 Filed 12-22-06; 8:45 am]
BILLING CODE 4830-01-P
